PH responsive drug conjugated nanocarriers
US12115180B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 1, 2021 |
| Grant date | Oct 15, 2024 |
| Priority date | — |
| Expiry date | Mar 1, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The presently disclosed invention relates to products and methods of treating cancer in a patient comprising administering to the patient a pharmaceutically therapeutic dose of a chemotherapeutic, or any pharmaceutically acceptable salt, solvate, or prodrug thereof, conjugated to a nanocarrier. According to a further embodiment, the chemotherapeutic has a primary (1°) amine (—NH2) group in within a pharmaceutical structure of the chemotherapeutic structure. According to a further embodiment, the chemotherapeutic is one of a platinum-based pharmaceutical and an Anthracycline family pharmaceutical. According to a further embodiment, the chemotherapeutic is one of gemcitabine, methotrexate, cisplatin, oxaliplatin, doxorubicin, daunorubicine, idarubicine, and epirubicine. According to a further embodiment, the chemotherapeutic is either attached to the nanocarrier by means that includes covalent bonds or is attached by means that does not included covalent bonds. According to a further embodiment, the nanocarrier is a pH-sensitive nanocarrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.